Blue Jet Healthcare Limited (BLUEJET) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Blue Jet Healthcare Limited stock ₹153, price ₹544, that is 71.9% below the price, quality 52 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.
How to read this chart
36‑month range ₹320.92 – ₹1,008 · fair‑value band ₹95.63 – ₹230.03 · the ₹543.55 price screens above the ₹152.53 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.
Follow Blue Jet Healthcare in your weekly email
Every Wednesday you see whether Blue Jet Healthcare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products.
Show moreShow less
It provides contrast media intermediates; niche pharmaceutical intermediates and APIs; and CDMO/CMO services, as well as end-to-end solutions from process development and commercialization of NCEs, advance intermediates, API, and building blocks.
The company develops, manufactures, and markets saccharin and related salts. It has operations in India, Norway, France, the United States, Italy, Sweden, and internationally. Blue Jet Healthcare Limited was incorporated in 1968 and is headquartered in Thane, India.
Stock analysis
Blue Jet Healthcare Limited (BLUEJET) currently trades at ₹543.55, while our model-based Fair Value estimate is ₹152.53, 72% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹281.50 per share, and 0 of the 26 models we run sit above the ₹543.55 price.
Bear case: the Asset-Based group reads lowest at ₹38.96, and 26 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: ₹95.63 (bear) to ₹230.03 (bull), the price of ₹543.55 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Blue Jet Healthcare Limited reported revenue of ₹9.5B in FY2026 versus ₹6.8B in FY2022, a compound +8.8%/yr. Reported net income was ₹2.5B in FY2026, compounding +8.1%/yr from FY2022.
Key figures
Market cap ₹94.3B (≈ $1.0B) Small · P/E ratio 40.1 · P/S ratio 10.6 · EPS (TTM) ₹13.55 · Dividend yield 0.2% · Net margin 26.5% · Return on equity 19.9% · Return on assets (EBIT) 25.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 85 out of 100 (low confidence).
What moves the price
The share trades about 13% below its 52-week high and 66% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −72%, BLUEJET screens richer than that median.
Fair Value models
Bear₹95.63Fair Value ₹152.53Bull₹230.03
Price ₹543.55 · Downside -71.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (₹7.61 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−8.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.9%
Start year 2021 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.9%
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +6.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+6.1%
Dividend (yield on the price)0.2%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.38% → 29%
⚠ Rate on operating basis: 2026 sits 51% above its own trend.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+44.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+13.5%
Yearly sales growth analysts expect, extended to five years.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +39.1% a year for the price and +9.0% for the forecasts.
Compare Blue Jet Healthcare Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks
Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score52 · Top 25%
Fair Value upside−71.9% · Bottom 25%
Profitability
Return on equity (12 months)19.9% · Top 25%
Return on assets15.1% · Top 25%
Net margin (12 months)26.5% · Top 25%
Operating margin (12 months)31.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)−17.4% · Bottom 25%
Dividend yield (12 months)0.2% · Bottom 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Blue Jet Healthcare Limited (BLUEJET) overvalued or undervalued?
As of Nov 11, 2026, our model estimates a fair value of ₹152.53 versus a price of ₹543.55, about 72% lower (overvalued).
What is the fair value of BLUEJET?
Our model-based fair value for Blue Jet Healthcare Limited is ₹152.53 (as of Nov 11, 2026), built from audited fundamentals. The current price: ₹543.55.
What is the quality score of BLUEJET?
Blue Jet Healthcare Limited has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Blue Jet Healthcare Limited (BLUEJET)?
Our model-based price target is the fair value of ₹152.53 (as of Nov 11, 2026) from 26 valuation models. Cautious scenario ₹95.63, optimistic scenario ₹230.03. It is a calculation from audited fundamentals, not an analyst target.
What is the Blue Jet Healthcare Limited stock forecast for 2026?
Our models put fair value at ₹152.53, about 72% lower versus a price of ₹543.55 (overvalued). Cautious scenario ₹95.63, optimistic scenario ₹230.03. The calculation is refreshed regularly with new filings.
What is the revenue of Blue Jet Healthcare Limited (BLUEJET)?
Blue Jet Healthcare Limited reported trailing-twelve-month revenue of about ₹8.9B (latest available figure, as of Nov 11, 2026).
Does Blue Jet Healthcare Limited pay a dividend?
Blue Jet Healthcare Limited currently shows a dividend yield of 0.22% relative to its recent price (as of Nov 11, 2026).
How much is the dividend of Blue Jet Healthcare Limited (BLUEJET) and when is the ex-dividend date?
Blue Jet Healthcare Limited pays a dividend of ₹1.20 per share a year, a dividend yield of 0.2%. The last ex-dividend date was Sep 11, 2026. The payout ratio is 8.9% of earnings. Free cash flow covers the dividend 5.51 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Blue Jet Healthcare Limited (BLUEJET)?
For today's price to be fair in a discounted-cash-flow model, Blue Jet Healthcare Limited would have to grow free cash flow by +44.9 % per year for five years (discount rate 12.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +13.9 % per year. As of Nov 11, 2026.
What discount rate (WACC) does the fair value of BLUEJET use?
Our models discount Blue Jet Healthcare Limited at 12.6 %: a base by market capitalisation (small), damped by beta 0.64, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Blue Jet Healthcare Limited that is +44.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.6 %) and the same formula as our fair value.
How much growth has Blue Jet Healthcare Limited (BLUEJET) delivered so far?
Over the past 5 years revenue at Blue Jet Healthcare Limited grew +13.9 % a year. The price currently implies free-cash-flow growth of +44.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Blue Jet Healthcare Limited (BLUEJET) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Blue Jet Healthcare Limited (+44.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Blue Jet Healthcare Limited (BLUEJET)?
The free-cash-flow yield on the price is 1.22 %: that much free cash flow Blue Jet Healthcare Limited produces per unit of market value. When it exceeds the discount rate of our models (12.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Blue Jet Healthcare Limited (BLUEJET)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Blue Jet Healthcare Limited it is ₹152.53 per share (as of Nov 11, 2026), against a price of ₹543.55. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Blue Jet Healthcare Limited stock overvalued or undervalued in 2026?
As of Nov 11, 2026, BLUEJET trades above its calculated fair value: price ₹543.55, fair value ₹152.53, a gap of about −72% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BLUEJET?
No. The price is what the market pays today (₹543.55); the fair value is what the company's own numbers justify (₹152.53). For Blue Jet Healthcare Limited the two are ₹391.02 per share apart. That gap is exactly why we show both numbers side by side.
How much is Blue Jet Healthcare Limited worth?
The market values Blue Jet Healthcare Limited at about ₹94.3B (market capitalisation, as of Nov 11, 2026). Per share that is ₹543.55; our models calculate a fair value of ₹152.53 per share.
What do the bullish and bearish scenarios say about BLUEJET?
Our models span a range for Blue Jet Healthcare Limited: cautious scenario ₹95.63, base ₹152.53, optimistic ₹230.03 per share (as of Nov 11, 2026, price ₹543.55). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BLUEJET?
Blue Jet Healthcare Limited trades at a price-to-earnings ratio of 40.1 (as of Nov 11, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹152.53 is built from several models across several years. Other multiples: P/B 6.9, P/S 10.6, EV/EBITDA 34.3.
How solid is the balance sheet of Blue Jet Healthcare Limited (BLUEJET)?
Balance-sheet figures for Blue Jet Healthcare Limited (as of Nov 11, 2026): return on equity 19.9%. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is BLUEJET from its 52-week high?
Blue Jet Healthcare Limited trades at ₹543.55, about 13% below its 52-week high of ₹626.25 and 66% above the low of ₹327.25 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of ₹152.53 is for.
Which stocks are comparable to Blue Jet Healthcare Limited?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Blue Jet Healthcare Limited stock attractive at the current price?
The data as of Nov 11, 2026: price ₹543.55, calculated fair value ₹152.53 (−72%), Quality Score 52/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BLUEJET calculated?
We run Blue Jet Healthcare Limited through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹152.53 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Blue Jet Healthcare Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Blue Jet Healthcare Limited (BLUEJET)?
The closing price on Nov 9, 2026 was ₹543.55. Our model-based fair value is ₹152.53, about 72% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Blue Jet Healthcare Limited right now?
The price sits above even our optimistic bull case (₹230.03). The favourable scenario is already priced in. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹95.63 to ₹230.03) leaves room in how you read the outcome.
Key figures of Blue Jet Healthcare Limited
How large is the market capitalisation of Blue Jet Healthcare Limited (BLUEJET)?
The market capitalisation of Blue Jet Healthcare Limited is ₹94.3B (≈ $1.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Blue Jet Healthcare Limited (BLUEJET)?
The price-to-sales ratio of Blue Jet Healthcare Limited is 10.6 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Blue Jet Healthcare Limited (BLUEJET)?
Earnings per share at Blue Jet Healthcare Limited are ₹13.55 (price ÷ EPS = P/E 40.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Blue Jet Healthcare Limited (BLUEJET)?
The dividend yield of Blue Jet Healthcare Limited is 0.2% (payout 8.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Blue Jet Healthcare Limited (BLUEJET)?
The net margin of Blue Jet Healthcare Limited is 26.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Blue Jet Healthcare Limited (BLUEJET)?
The return on equity (ROE) of Blue Jet Healthcare Limited is 19.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Blue Jet Healthcare Limited (BLUEJET)?
On an EBIT basis the return on assets of Blue Jet Healthcare Limited is 25.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Blue Jet Healthcare Limited (BLUEJET)?
The operating margin of Blue Jet Healthcare Limited is 31.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Blue Jet Healthcare Limited (BLUEJET)?
Revenue at Blue Jet Healthcare Limited is growing −17.4% versus a year earlier (3y avg +9.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Blue Jet Healthcare Limited (BLUEJET)?
Earnings per share at Blue Jet Healthcare Limited are growing −14.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Blue Jet Healthcare Limited (BLUEJET) hold?
Blue Jet Healthcare Limited holds more cash than debt, ₹1.1B net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Blue Jet Healthcare Limited in the live analysis
One click puts Blue Jet Healthcare Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 11, 2026